← Leaderboards
Damian J. Green
Fred Hutchinson Cancer Center
$13,222,447
Attributed
$13,793,126
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,793,126 · 7
By mechanism
R01$6,334,927 · 3
P01$6,269,928 · 2
K08$847,800 · 1
R21$340,471 · 1
Top collaborators
- Brian Till3 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Frederick R Appelbaum$23,398,619
- Ajay Gopal$4,782,402
- Stanley R Riddell$31,084,866
- George S Laszlo$485,634
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseResponseRelapseToxic EffectRadioimmunotherapyMonoclonal AntibodiesNeoplastic CellPre-ClinicalAntibodiesHigh RiskDiagnosisS LymphomaClinical TrialsMultiple MyelomaCellsRadiationPlasma CellsDepositionDisease RemissionRadiolabeledCharacteristicsMouse ModelRadioisotopesTreatment Efficacy
Grant awards (35)
Radioimmunotherapy Combinations for B-cell Malignancy$386,220
R01 · FY2025 · CA · contact PI
Project 3: Integrating Plasma Cell-Specific Radioimmunotherapy into Allogeneic Stem Cell Transplantation for Myeloma$291,812
P01 · FY2025 · CA · contact PI
Radioimmunotherapy Combinations for B-cell Malignancy$301,797
R01 · FY2024 · CA · contact PI
Radioimmunotherapy Combinations for B-cell Malignancy$90,678
R01 · FY2024 · CA · contact PI
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma$413,248
R01 · FY2023 · CA · contact PI
Radioimmunotherapy Combinations for B-cell Malignancy$413,131
R01 · FY2023 · CA · contact PI
Project 3: Integrating Plasma Cell-Specific Radioimmunotherapy into Allogeneic Stem Cell Transplantation for Myeloma$330,053
P01 · FY2023 · CA · contact PI
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma$862,729
P01 · FY2022 · CA · contact PI
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma$356,167
R01 · FY2022 · CA · contact PI
Radioimmunotherapy Combinations for B-cell Malignancy$351,428
R01 · FY2022 · CA · contact PI
Project 3: Integrating Plasma Cell-Specific Radioimmunotherapy into Allogeneic Stem Cell Transplantation for Myeloma$315,956
P01 · FY2022 · CA · contact PI
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma$56,218
R01 · FY2022 · CA · contact PI
Radioimmunotherapy Combinations for B-cell Malignancy$53,440
R01 · FY2022 · CA · contact PI
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma$859,480
P01 · FY2021 · CA · contact PI
Radioimmunotherapy Combinations for B-cell Malignancy$431,181
R01 · FY2021 · CA · contact PI
Project 3: Integrating Plasma Cell-Specific Radioimmunotherapy into Allogeneic Stem Cell Transplantation for Myeloma$330,052
P01 · FY2021 · CA · contact PI
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma$327,515
P01 · FY2021 · CA · contact PI
Project 3: Integrating Plasma Cell-Specific Radioimmunotherapy into Allogeneic Stem Cell Transplantation for Myeloma$241,565
P01 · FY2021 · CA · contact PI
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma$861,992
P01 · FY2020 · CA · contact PI
Project 3: Integrating Plasma Cell-Specific Radioimmunotherapy into Allogeneic Stem Cell Transplantation for Myeloma$277,170
P01 · FY2020 · CA · contact PI
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma$775,192
P01 · FY2019 · CA · contact PI
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma$629,947
R01 · FY2019 · CA · contact PI
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma$796,412
P01 · FY2018 · CA · contact PI
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma$656,744
R01 · FY2018 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$379,044
R01 · FY2018 · CA · contact PI
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma$697,579
R01 · FY2017 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$379,044
R01 · FY2017 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$383,270
R01 · FY2016 · CA · contact PI
CD38 Pretargeted Radioimmunotherapy for Myeloma$355,791
R01 · FY2015 · CA · contact PI
Radioimmunotherapy for Multiple Myeloma$169,560
K08 · FY2014 · CA · contact PI
Radioimmunotherapy for Multiple Myeloma$169,560
K08 · FY2013 · CA · contact PI
Targeted Radiotherapy with 90Y-BC8 Monclonal Antibody, Fludarabine and TBI Follow$340,471
R21 · FY2012 · CA · contact PI
Radioimmunotherapy for Multiple Myeloma$169,560
K08 · FY2012 · CA · contact PI
Radioimmunotherapy for Multiple Myeloma$169,560
K08 · FY2011 · CA · contact PI
Radioimmunotherapy for Multiple Myeloma$169,560
K08 · FY2010 · CA · contact PI